Sino Biopharmaceutical announced drug development and sales pacts with two UK pharma companies on Wednesday. One will see the Hong Kong biotech license an investigational PDE3/4 inhibitor to AstraZeneca for $200 …
Source: Endpoints News
You may also like
SMC recommends VEOZA for moderate to severe menopausal...
SMC backs Columvi combination for second-line lymphoma...
Bristol Myers Squibb’s New Drug Application for...
Exonate appoints Olav Hellebø as CEO
Genetic Map Opens Door to Development of New Therapies...
StockWatch: Insilico Projects Profit, Revenue Leaps as...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.